Autoimmune Monoclonal Antibody Market on Track for Strong Growth, Estimated to Grow at 8.1% CAGR Through 2029

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Autoimmune Monoclonal Antibody Market Through 2025?
Recent years have seen a significant surge in the size of the autoimmune monoclonal antibody market. Predictions suggest that it will rise from $65.83 billion in 2024 to $70.86 billion in 2025, recording a compound annual growth rate (CAGR) of 7.6%. This growth trajectory in the historic period can be traced back to factors such as heightened prevalence of autoimmune diseases, escalated use of biologics for treatment, increased cognizance of targeted therapies, advanced approvals for monoclonal antibody drugs, and enhanced healthcare accessibility in developed nations.

What's the Projected Size of the Global Autoimmune Monoclonal Antibody Market by 2029?
Strong expansion is projected for the autoimmune monoclonal antibody market size in the coming years, with an anticipated growth to "$96.74 billion by 2029," reflecting a compound annual growth rate (CAGR) of 8.1%. The growth during the prognosis period is likely due to a surge in demand for bespoke medicine, increased adoption of biosimilars, the broadening scope of clinical trials in autoimmune therapies, an aging population, and a higher incidence of chronic immune disorders. Noteworthy trends for the prediction period include advancements in antibody engineering, the creation of bispecific antibodies, the expanding application of artificial intelligence in pharmaceutical discoveries, the inclusion of genomics in treatment strategizing, and inventive drug delivery systems.

View the full report here:
https://www.thebusinessresearchcompany.com/report/autoimmune-monoclonal-antibody-global-market-report

Top Growth Drivers in the Autoimmune Monoclonal Antibody Industry: What's Accelerating the Market?
The surge in demand for biologics is anticipated to drive the expansion of the autoimmune monoclonal antibody market. Biologics are a type of medical product originating from living organisms, used in the diagnosis, prevention, and treatment of diseases. The growth in demand for biologics predominantly stems from their proficiency in treating complex diseases such as genetic conditions, cancer, and autoimmune disorders, where conventional therapies could be less successful. Autoimmune monoclonal antibodies fortify biologic therapies by offering concentrated immune modulation, marking them effective for keeping overactive immune responses in check. They lessen the reliance on extensive immunosuppressants by providing precise treatment, boosting patient outcomes, and diminishing side effects. For example, Cardinal Health Inc., a healthcare company based in the US, reported in June 2024 that out of 40 biosimilar products approved by the Food and Drug Administration (FDA) in 2023, 25 are presently accessible in the US market. This is a rise from the 33 biosimilar products in 2022. Hence, the escalation in demand for biologics underpins the growth of the autoimmune monoclonal antibody market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24162&type=smp

What Are the Key Trends Driving Autoimmune Monoclonal Antibody Market Growth?
Leading firms in the autoimmune monoclonal antibody market are concentrating on the development of groundbreaking solutions like biosimilar development to improve safety, efficacy, and quality. The concept of biosimilar development involves the creation of comparable, safe, and efficient biological products to approved biologics, through sophisticated biotechnology, thorough analytical testing, and clinical trials to show similar quality, efficacy, and safety for regulatory authorization. For example, in February 2025, Indian biopharmaceutical corporation, Biocon Biologics Limited, introduced YESINTEK, a biosimilar designed to address autoimmune disorders such as Crohn's disease, ulcerative colitis, and psoriasis. It works by targeting and limiting the activity of interleukin-12 and interleukin-23, thus reducing inflammation and coordinating the immune response. By closely replicating the reference product, stelara, Yesintek aids in long-term disease control while expanding patient access to biologic therapies.

What Are the Main Segments in the Autoimmune Monoclonal Antibody Market?
The autoimmune monoclonal antibody market covered in this report is segmented -

1) By Type: Immunoglobulin G Monoclonal Antibodies, Immunoglobulin M Monoclonal Antibodies, Chimeric Monoclonal Antibodies, Fully Human Monoclonal Antibodies
2) By Route Of Administration: Subcutaneous, Intravenous, Intramuscular
3) By Application: Rheumatoid Arthritis, Multiple Sclerosis, Systemic Lupus Erythematosus, Psoriasis, Inflammatory Bowel Disease
4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
5) By End User: Hospitals, Outpatient Clinics, Homecare Settings, Research Institutions

Subsegments:
1) By Immunoglobulin G (IgG) Monoclonal Antibodies: Immunoglobulin G1 (IgG1), Immunoglobulin G2 (IgG2), Immunoglobulin G3 (IgG3), Immunoglobulin G4 (IgG4)
2) By Immunoglobulin M (IgM) Monoclonal Antibodies: Pentameric Immunoglobulin M (IgM), Hexameric Immunoglobulin M (IgM)
3) By Chimeric Monoclonal Antibodies: Murine Variable Region + Human Constant Region, Humanized Variable Region + Murine Constant Region
4) By Fully Human Monoclonal Antibodies: Phage Display-Derived, Transgenic Mouse-Derived, Fully Human Hybridoma-Derived

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=24162&type=smp

Which Top Companies are Driving Growth in the Autoimmune Monoclonal Antibody Market?
Major companies operating in the autoimmune monoclonal antibody market are Johnson & Johnson, F. Hoffmann-La Roche Ltd, Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., UCB S.A., Genmab A/S, Zymeworks Inc., Xencor Inc., Immutep Limited, Cue Biopharma Inc., Santa Ana Bio Inc.

Which Regions Will Dominate the Autoimmune Monoclonal Antibody Market Through 2029?
North America was the largest region in the autoimmune monoclonal antibody market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the autoimmune monoclonal antibody market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24162

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.